In quick turnaround, FDA lifts full clinical hold on Protagonist’s blood cancer program

Not even a month after being slapped with a full clinical hold on all studies related to a blood cancer program, Protagonist Therapeutics saw regulators reverse course.

Protagonist’s experimental drug rusfertide is cleared to resume dosing in all studies, the biotech announced Monday morning, paving the way for researchers to...

Click to view original post